A selection of awards recently earned by Dana-Farber and our staff
A new Brain Cancer SPORE (Specialized Program of Research Excellence) has been awarded by the National Cancer Institute to Mass General and Dana-Farber Cancer Institute. Each SPORE focuses on a specific organ site or on cancers that are highly related. This DF/HCC SPORE program will utilize an extensive array of preclinical models, clinical materials, and molecular profiling platforms to develop multiple, early phase, targeted therapy trials for glioblastoma.
On August 27 and 28, Dana-Farber held its 12th annual WEEI/NESN Jimmy Fund Radio Telethon, raising more than $3.3 million for adult and pediatric care and cancer research at Dana-Farber.
Last year, more than 99 percent of Dana-Farber staff received a flu vaccine, giving DFCI the highest vaccination rate in 2012 for Massachusetts hospitals — a success reported in the September 21 Boston Globe.
U.S. News & World Report's Best Hospitals guide has ranked Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) the top cancer center in New England for the 13th straight year, and fifth overall in the country.
Thanks to efforts by staff in Human Resources and the Gay, Lesbian, Bisexual and Transgender Employee Resource Group (GLBT ERG), Dana-Farber recently achieved a perfect score in a nationwide survey by the Human Rights Campaign (HRC) and has been recognized as a "Leader in LGBT Healthcare Equality."
Approximately 8,500 people from across New England and beyond — including an impressive number of Dana-Farber staff — enjoyed camaraderie for a cause during the 25th annual Boston Marathon® Jimmy Fund Walk presented by Hyundai on September 8.
Four Dana-Farber physician-researchers and a consortium that includes several Institute investigators have been awarded more than $1.9 million in research grants by the St. Baldrick's Foundation, which supports pediatric cancer research. Recipients include Soad Fuentes Alabi, MD, who is studying the epidemiology and biology of childhood cancer in South America and is establishing a cancer registry in El Salvador and other countries in Central America; Kira Bona, MD, who is identifying social factors that contribute to childhood cancer mortality and studying how poverty affects the families of children with cancer; Brian Crompton, MD, whose team recently identified a protein that is highly active in Ewing sarcoma and is targeted by drugs in clinical development; and Xiaofeng Wang, PhD, who is studying the role of the mutated gene SNF5 in the formation of rhabdoid tumors. Another grant was awarded to the Pediatric Blood and Marrow Transplant Late Effects Consortium, a group of researchers at 28 institutions studying the late effects of childhood stem cell transplantation, with the goal of improving long-term survival. The funds will be administered by Dana-Farber to all participating institutions.
Bruce M. Spiegelman, PhD, Stanley J. Korsmeyer Professor of Cell Biology and Medicine, Harvard Medical School, is the winner of the 2013 Manpei Suzuki International Prize for his groundbreaking contributions to many landmark discoveries in adipocyte biology and energy homeostasis, which serve as the basis of a fundamental understanding of type 2 diabetes.Four representatives from the Dana-Farber/Boston Children's Cancer and Blood Disorders Center Global Health Initiative recently visited the Dominican Republic to evaluate its partnership with the Dr. Arturo Grullón Regional Children's Hospital in Santiago. The team included Irini Albanti, MPH, manager of the GHI; Paola Friedrich-Medina, MD, MPH, a pediatric oncologist; Lisa Morrissey, MPH, MSN, a pediatric oncology nurse manager; and Christopher Weldon, MD, PhD, a pediatric oncology surgeon.
Natasha Archer, MD, a Fellow of the Global Health Initiative and a Clinical Fellow in Pediatric Hematology-Oncology at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, collaborated with Phouc Le, MD, MPH, an assistant professor and attending physician at the University of California San Francisco School of Medicine, in authoring a chapter in a newly released book, Building Partnerships in the Americas.
Recipients of Young Investigator Awards were announced at the American Society of Clinical Oncology annual meeting in Chicago. Of the 44 awardees, 11 — comprising a quarter of the whole group — are fellows in the Dana-Farber/Partners CancerCare Hematology/Oncology Fellowship Program. They are: Ami Bhatt, MD; Kira Bona, MD; Gabriel Brooks, MD; Curtis Chong, MD; Adam Crystal, MD, PhD; Andrea Enzinger, MD; Aaron Hata, MD, PhD; Mandar Muzumdar, MD; Supriya Saha, MD, PhD; Eliezer Van Allen, MD; and Cesar Serrano, MD.
The Women's Bar Association (WBA) of Massachusetts has chosen Dana-Farber Associate General Counsel Kara DelTufo to serve as its president-elect. DelTufo was elected to the position at the WBA annual meeting and reception. Her position as president-elect means that she will serve as WBA president in 2014-2015.
Karen Emmons, PhD, who holds joint appointments at Dana-Farber and the Harvard School of Public Health (HSPH), was honored by HSPH for her service in mentoring junior faculty.
Levi Garraway, MD, PhD, was named one of three recipients of the Paul Marks Prize for Cancer Research, which is awarded annually by Memorial Sloan-Kettering Cancer Center to recognize promising cancer investigators age 45 or younger.
The Leukemia and Lymphoma Society awarded Irene Ghobrial, MD, a one-year, $100,000 grant through its New Idea Award Program. Ghobrial, who is a medical oncologist in the Jerome Lipper Multiple Myeloma Center at Dana-Farber, will use the grant money to study why multiple myeloma cells target bone marrow. Ghobrial will work to develop therapies that prevent or delay the spread of multiple myeloma tumors by identifying what can inhibit these cells from attacking bone marrow.
Joanne Wolfe, MD, MPH, has been awarded the American Cancer Society's 2013 Pathfinder in Palliative Care Award, for demonstrating remarkable innovation and ingenuity that advance the palliative care field. Wolfe is the founder of the Pediatric Advanced Care Team (PACT) at Dana-Farber/Boston Children's Cancer and Blood Disorders Center; she is Director of Pediatric Palliative Care at Boston Children's Hospital and Division Chief of the Pediatric Palliative Care Service at Dana-Farber Cancer Institute.
Anne H. Gross, PhD, RN, and Patricia Branowicki, MS, RN, will be inducted as Fellows to the American Academy of Nursing at the organization's 40th annual meeting in October. The two will join six other nurses from Massachusetts at the Washington, D.C., event, which is one of nursing's most prestigious honors.
The Arnold P. Gold Foundation for Humanism in Medicine honored Jennifer Kesselheim, MD, M.Ed, MBE, with a $150,000 grant as part of the Arnold P. Gold Foundation Professorship Program. Kesselheim was one of three recipients of the annual "Gold Professor" Award. Each year, the Arnold P. Gold Foundation Professorship Awards are given to assistant or associate professors who embody the foundation's mission of "humanistic" medicine and professionalism in medical education.
David Kozono, MD, PhD, of Dana-Farber's Department of Radiation Oncology, received a 2013 Career Development Award for Translational Research from the LUNGevity Foundation.
Carl Novina, MD, PhD, a researcher in the Department of Cancer Immunology and AIDS, was awarded a one-year, $100,000 grant through the American Society of Hematology Bridge Grant program. Novina is one of 14 recipients in the second round of ASH Bridge Grants, which support hematologic research that has lost funding due to budget cuts at the National Institutes of Health. The hematologists who received the grants were among a group of researchers whose NIH grant applications scored well, but missed the funding cutoff due to a $1.6 billion reduction in federal funding.
Oreofe Odejide, MD, a hematology/oncology fellow in Dana-Farber's Department of Medical Oncology, is one of 21 young physicians selected by the American Society of Hematology for its 2013 Clinical Research Training Institute.
John Quackenbush, PhD, was honored as an Open Science Champion of Change at a White House Ceremony in June. He was one of 13 scientists, including seven genomic and molecular biology researchers, honored for their work in making large and complex data sets accessible to a broader scientific community.
Geoffrey Shapiro, MD, PhD, received an award from the National Cancer Institute in recognition of his contributions to the development of novel agents for cancer therapy. Shapiro, director of the Early Drug Development Center at Dana-Farber since 2007, received the 2013 Michaele C. Christian Oncology Development Award and Lectureship on September 9.
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: